Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

Abstract

Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and ectopic fat, common features of chronic obstructive pulmonary disease (COPD), might contribute to the development of NAFLD.We aimed to investigate the prevalence of NAFLD and to evaluate the relationship between various types of liver damage and COPD severity, comorbidities and circulating inflammatory cytokines. Validated noninvasive tests (FibroMax: SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH) and liver fibrosis. Patients underwent an objective assessment of COPD comorbidities, including sleep studies. Biological parameters included a complete lipid profile and inflammatory markers.In COPD patients the prevalence of steatosis, NASH and fibrosis were 41.4%, 36.9% and 61.3%, respectively. In multivariate analysis, SteatoTest and FibroTest were significantly associated with sex, body mass index (BMI), untreated sleep apnoea and insulin resistance, and, in addition, COPD Global Initiative for Chronic Obstructive Lung Disease stage for SteatoTest. Patients with steatosis had higher tumour necrosis factor-α levels and those with NASH or a combination of liver damage types had raised leptin levels after adjustment for age, sex and BMI.We concluded that NAFLD is highly prevalent in COPD and might contribute to cardiometabolic comorbidities.

Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007–2010

“…The difference in the prevalences of NAFLD may be due to differences in the study population (eg, age and urban-dwelling area) and method (eg, ultrasonography and LFS). Additionally, in a previous study, the prevalence of OLD among 13,835 American adult subjects aged 19–80 years was 11.8%,23 and it was 13.1% in a study of 16,151 adults in Korea aged ≥40 years 24. The prevalence of OLD in this study was 8.9%.…”

<p>Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis</p>

“…Despite the potential two-way relationship between COPD and liver steatosis due to chronic low-grade inflammation, intermittent hypoxia and induced adipokines, 24,25 few data are available to draw an epidemiologic picture of liver steatosis in this population. In a previous study, 26 we reported that the liver fibrosis stage of non-alcoholic fatty liver disease, but not steatosis, is an independent factor of cardiovascular morbidity in COPD, in line with results in the general population.…”

Ендотеліальна Дисфункція Та Морфофункціональні Властивості Еритроцитів При Неалкогольному Стеатогепатиті, Поєднаному З Хронічним Обструктивним Захворюванням Легень, У Хворих На Ожиріння

“…В декількох до-слідженнях повідомляється про зв'язок НАЖХП із функціональним станом легень, у тому числі про її асоціацію з ХОЗЛ [15][16][17][18][19][20][21].…”

“…У цьому контексті Viglino et al [16] виявили, що НАЖХП дуже поширена у хворих на ХОЗЛ і може спричиняти кардіометаболічні супутні захворю-вання. Це проспективне когортне дослідження проведено в 111 дорослих пацієнтів із легким та Точно прогнозувати розвиток значного (≥ F2) фіброзу в пацієнтів із НАЖХП можна також за до-помогою визначення вмісту sVCAM-1 у сироватці крові [22].…”